Preventive Cardiology

Is Moderate Exercise Safe on Statins?

Statin users commonly experience muscle pain and weakness, and previous research has shown that they risk muscle damage by participating in strenuous exercise. But an interesting new study out of the Netherlands revealed that statins don’t exacerbate muscle-related harms from prolonged moderate-intensity exercise, and statin-associated muscle symptoms (SAMS) shouldn’t stand in the way of physical activity.

The researchers recruited 100 people in their 60s (35 statin users with SAMS, 34 statin users without SAMS, 31 healthy controls) to be evaluated while participating in Nijmegen, Netherlands’ 4Days March, which requires four daily walks of 18.6 to 31 miles. 

Surprisingly to some observers, each group had similar…

  • Increases in muscle injury biomarkers
  • Decreases in handgrip strength and muscle peak force
  • Levels of Leukocyte CoQ10… and CoQ10 levels weren’t associated with muscle injury markers, fatigue resistance, or muscle symptoms
  • Increases in muscle pain scores, although statin users with SAMS had higher baseline muscle pain scores

Statin users might still risk muscle injuries with strenuous exercise, but these findings suggest that “moderate” exercise (like four straight 31-mile walks) doesn’t damage statin users’ muscles, while reinforcing recommendations to combine statin therapy with a physically active lifestyle. 

The Takeaway

Statin-associated muscle symptoms earned its own medical abbreviation (SAMS) for a reason, and concerns about statin’s muscle risks are well established. That’s what makes the findings of this study so beneficial from a patient and clinician education standpoint, especially if it helps get more statin users exercising.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

Cardiology Pharmaceuticals August 18, 2025

Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025

New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]

Surgeries & Interventions August 14, 2025

TEER Could Save Lives in AFMR Patients August 14, 2025

Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!